Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis

Journal of Medicinal Chemistry

Volumn 56, Issue 23, 2013, Pages 9403-9414

  Bonnac, Laurent F ^a   Mansky, Louis M ^b   Patterson, Steven E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 N AMINOCYTIDINE; 4 N HYDROXYCYTIDINE; 4 N HYDROXYDEOXYCYTIDINE; 5 AZA 2' DEOXYCYTIDINE; 5 BROMOURIDINE; 5 FORMYLDEOXYCYTIDINE; 5 FORMYLDEOXYURIDINE; 5 FORMYLURIDINE; 5 HYDROXYCYTIDINE; 5 HYDROXYDEOXYCYTIDINE; 5 TRIFLUOROMETHYLURIDINE; 5,6 DIHYDROCYTIDINE; 5,6 DIHYDRODEOXYCYTIDINE; 6 HYDROXYDEOXYADENOSINE; 6 METHOXYADENOSINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE; BICYCLODEOXYCYTIDINE; BROXURIDINE; ETHENOADENOSINE; ETHENODEOXYADENOSINE; FLUOROURIDINE; IODOURIDINE; KP 1212; MUTAGENIC AGENT; NUCLEOSIDE DERIVATIVE; PROMUTAGEN; RIBAVIRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIF PROTEIN; VIRAL MUTAGEN; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG TARGETING; IONIZATION; LETHAL MUTAGENESIS; MUTAGENESIS; MUTAGENICITY; MUTATION RATE; NONHUMAN; PROTEIN PROTEIN INTERACTION; RETROVIRUS; REVIEW; RIBOVIRUS; RNA VIRUS; STRUCTURE ACTIVITY RELATION; TAUTOMER; VIRUS MUTATION; VIRUS VIABILITY; VIRUS VIRULENCE;

EID: 84890511278     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400653j     Document Type: Review

References (140)

1. De Clercq, E. Antivirals: past, present and future Biochem. Pharmacol. 2013, 85, 727-744
2. Moyle, P. M.; Toth, I. Modern subunit vaccines: development, components, and research opportunities ChemMedChem 2013, 8, 360-376
3. Calland, N.; Dubuisson, J.; Rouille, Y.; Seron, K. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses 2012, 4, 2197-2217
4. DeClercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 2009, 33, 307-320
5. Michaud, V.; Bar-Magen, T.; Turgeon, J.; Flockhart, D.; Desta, Z.; Wainberg, M. A. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition Pharmacol. Rev. 2012, 64, 803-833
6. Vignuzzi, M.; Stone, J. K.; Arnold, J. J.; Cameron, C. E.; Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population Nature 2006, 439, 344-348
7. Eigen, M. Error catastrophe and antiviral strategy Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13374-13376
8. Biebricher, C. K.; Eigen, M. The error threshold Virus Res. 2005, 107, 117-127
9. Holland, J. J.; Domingo, E.; De La Torre, J. C.; Steinhauer, D. A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis J. Virol. 1990, 64, 3960-3962
10. Loeb, L. A.; Mullins, J. I. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs AIDS Res. Hum. Retroviruses 2000, 16, 1-3
11. Iranzo, J.; Perales, C.; Domingo, E.; Manrubia, S. C. Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 16008-16013
12. Ojosnegros, S.; Perales, C.; Mas, A.; Domingo, E. Quasispecies as a matter of fact: viruses and beyond Virus Res. 2011, 162, 203-215
13. Perales, C.; Martin, V.; Domingo, E. Lethal mutagenesis of viruses Curr. Opin. Virol. 2011, 1, 419-422
14. Dapp, M. J.; Patterson, S. E.; Mansky, L. M. Back to the future: revisiting HIV-1 lethal mutagenesis Trends Microbiol. 2013, 21, 56-62
15. Negishi, K.; Bessho, T.; Hayatsu, H. Nucleoside and nucleobase analog mutagens Mutat. Res. 1994, 318, 227-238
16. Anderson, J. P.; Daifuku, R.; Loeb, L. A. Viral error catastrophe by mutagenic nucleosides Annu. Rev. Microbiol. 2004, 58, 183-205
17. Iyidogan, P.; Anderson, K. S. Lethal Mutagenesis as an Unconventional Approach To Combat HIV. In Antiviral Drug Strategies; DeClercq, E., Ed.; Wiley-VCH: Weinheim, Germany, 2011; pp 283-306.
18. Benigni, R.; Bossa, C. Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology Chem. Rev. 2011, 111, 2507-2536
19. Ferguson, L. R.; Denny, W. A. Genotoxicity of non-covalent interactions: DNA intercalators Mutat. Res. 2007, 623, 14-23
20. Nelson, S. M.; Ferguson, L. R.; Denny, W. A. Non-covalent ligand/DNA interactions: minor groove binding agents Mutat. Res. 2007, 623, 24-40
21. Li, H. H.; Aubrecht, J.; Fornace, A. J., Jr. Toxicogenomics: overview and potential applications for the study of non-covalent DNA interacting chemicals Mutat. Res. 2007, 623, 98-108
22. Dapp, M. J.; Clouser, C. L.; Patterson, S.; Mansky, L. M. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1 J. Virol. 2009, 83, 11950-11958
23. Clouser, C. L.; Chauhan, J.; Bess, M. A.; van Oploo, J. L.; Zhou, D.; Dimick-Gray, S.; Mansky, L. M.; Patterson, S. E. Resveratrol analogs and decitabine as combination therapy for HIV Bioorg. Med. Chem. Lett. 2012, 22, 6642-6646
24. Agarwal, R. P.; Busso, M. E.; Mian, A. M.; Resnick, L. Uptake of 2′,3′-dideoxyadenosine in human immunodeficiency virus-infected and noninfected human cells AIDS Res. Hum. Retroviruses 1989, 5, 541-550
25. Huber-Ruano, I.; Pastor-Anglada, M. Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity Curr. Drug Metab. 2009, 10, 347-358
26. Parkinson, F. E.; Damaraju, V. L.; Graham, K.; Yao, S. Y. M.; Baldwin, S. A.; Cass, C. E.; Young, J. D. Molecular biology of nucleoside transporters and their distributions and functions in the brain Curr. Top. Med. Chem. 2011, 11, 948-972
27. Paterson, A. R.; Kolassa, N.; Cass, C. E. Transport of nucleoside drugs in animal cells Pharmacol. Ther. 1981, 12, 515-536
28. Furman, P. A.; Fyfe, J. A.; St Clair, M. H.; Weinhold, K.; Rideout, J. L.; Freeman, G. A.; Lehrman, S. N.; Bolognesi, D. P.; Broder, S.; Mitsuya, H.; Barry, D. W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 8333-8337
29. Van Rompay, A. R.; Johansson, M.; Karlsson, A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases Pharmacol. Ther. 2000, 87, 189-198
30. Van Rompay, A. R.; Johansson, M.; Karlsson, A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases Pharmacol. Ther. 2003, 100, 119-139
31. Morales, J. C.; Kool, E. T. Varied molecular interactions at the active sites of several DNA polymerases: nonpolar nucleoside isosteres as probes J. Am. Chem. Soc. 2000, 122, 1001-1007
32. Kool, E. T. Active site tightness and substrate fit in DNA replication Ann. Rev. Biochem. 2002, 71, 191-219
33. Morales, J. C.; Kool, E. T. Minor groove interactions between polymerase and DNA: more essential to replication than Watson-Crick hydrogen bonds? J. Am. Chem. Soc. 1999, 121, 2323-2324
34. Silverman, A. P.; Garforth, S. J.; Prasad, V. R.; Kool, E. T. Probing the active site steric flexibility of HIV-1 reverse transcriptase: different constraints for DNA- versus RNA-templated synthesis Biochemistry 2008, 47, 4800-4807
35. Silverman, A. P.; Kool, E. T. RNA probes of steric effects in active sites: high flexibility of HIV-1 reverse transcriptase J. Am. Chem. Soc. 2007, 129, 10626-10627
36. Sintim, H. O.; Kool, E. T. Remarkable sensitivity to DNA base shape in the DNA polymerase active site Angew. Chem., Int. Ed. 2006, 45, 1974-1979
37. Seo, Y. J.; Romesberg, F. E. Major groove derivatization of an unnatural base pair ChemBioChem 2009, 10, 2394-2400
38. Crotty, S.; Maag, D.; Arnold, J. J.; Zhong, W.; Lau, J. Y.; Hong, Z.; Andino, R.; Cameron, C. E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Nat. Med. 2000, 6, 1375-1379
39. Cuevas, J. M.; Gonzalez-Candelas, F.; Moya, A.; Sanjuan, R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo J. Virol. 2009, 83, 5760-5764
40. Crotty, S.; Cameron, C. E.; Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6895-6900
41. Sidwell, R. W.; Huffman, J. H.; Khare, G. P.; Allen, L. B.; Witkowski, J. T.; Robins, R. K. Broad-spectrum antiviral activity of virazole: 1-beta- d -ribofuranosyl-1,2,4-triazole-3-carboxamide Science 1972, 177, 705-706
42. Sidwell, R. W.; Robins, R. K.; Hillyard, I. W. Ribavirin: an antiviral agent Pharmacol. Ther. 1979, 6, 123-146
43. Parker, W. B. Metabolism and antiviral activity of ribavirin Virus Res. 2005, 107, 165-171
44. Moreno, H.; Gallego, I.; Sevilla, N.; de la Torre, J. C.; Domingo, E.; Martin, V. Ribavirin can be mutagenic for arenaviruses J. Virol. 2011, 85, 7246-7255
45. Vignuzzi, M.; Stone, J. K.; Andino, R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications Virus Res. 2005, 107, 173-181
46. Balzarini, J.; Karlsson, A.; Wang, L.; Bohman, C.; Horska, K.; Votruba, I.; Fridland, A.; Van Aerschot, A.; Herdewijn, P.; De Clercq, E. Eicar (5-ethynyl-1-beta- d -ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis J. Biol. Chem. 1993, 268, 24591-24598
47. Lowe, J. K.; Brox, L.; Henderson, J. F. Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole Cancer Res. 1977, 37, 736-743
48. Balzarini, J.; Lee, C. K.; Herdewijn, P.; De Clercq, E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′- dideoxyinosine against human immunodeficiency virus J. Biol. Chem. 1991, 266, 21509-21514
49. Vivet-Boudou, V.; Paillart, J. C.; Burger, A.; Marquet, R. In search of new inhibitors of HIV-1 replication: synthesis and study of 1-(2′-deoxy- beta- d -ribofuranosyl)-1,2,4-triazole-3-carboxamide as a selective viral mutagenic agent Nucleosides, Nucleotides Nucleic Acids 2007, 26, 743-746
50. Branda, N.; Kurz, G.; Lehn, J.-M. JANUS WEDGES: a new approach towards nucleobase-pair recognition Chem. Commun. 1996, 2443
51. Asadi, A.; Patrick, B. O.; Perrin, D. M. Janus-AT bases: synthesis, self-assembly, and solid state structures J. Org. Chem. 2007, 72, 466-475
52. Pan, M. Y.; Hang, W.; Zhao, X. J.; Zhao, H.; Deng, P. C.; Xing, Z. H.; Qing, Y.; He, Y. Janus-type AT nucleosides: synthesis, solid and solution state structures Org. Biomol. Chem. 2011, 9, 5692-5702
53. Yang, H. Z.; Pan, M. Y.; Jiang, D. W.; He, Y. Synthesis of Janus type nucleoside analogues and their preliminary bioactivity Org. Biomol. Chem. 2011, 9, 1516-1522
54. Shin, D.; Tor, Y. Bifacial nucleoside as a surrogate for both T and A in duplex DNA J. Am. Chem. Soc. 2011, 133, 6926-6929
55. Hoogsteen, K. The crystal and molecular structure of a hydrogen-bonded complex between 1-methylthymine and 9-methyladenine Acta Crystallogr. 1963, 16, 907-916
56. Voet, D.; Rich, A. The Crystal Structures of Purines, Pyrimidines and Their Intermolecular Complexes. In Progress in Nucleic Acid Research and Molecular Biology; Davidson, J. N.; Waldo, E. C., Eds.; Academic Press: New York, 1970; Vol. 10, pp 183-265.
57. Tohyama, K. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes Curr. Pharm. Des. 2012, 18, 3190-3197
58. Tsujioka, T.; Yokoi, A.; Uesugi, M.; Kishimoto, M.; Tochigi, A.; Suemori, S.; Tohyama, Y.; Tohyama, K. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines Exp. Hematol. 2013, 41, 189-197
59. Clouser, C. L.; Patterson, S. E.; Mansky, L. M. Exploiting drug repositioning for discovery of a novel HIV combination therapy J. Virol. 2010, 84, 9301-9309
60. Jackson-Grusby, L.; Laird, P. W.; Magge, S. N.; Moeller, B. J.; Jaenisch, R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4681-4685
61. Rogstad, D. K.; Herring, J. L.; Theruvathu, J. A.; Burdzy, A.; Perry, C. C.; Neidigh, J. W.; Sowers, L. C. Chemical decomposition of 5-aza-2′- deoxycytidine (decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry Chem. Res. Toxicol. 2009, 22, 1194-1204
62. Pískala, A.; Hanna, N. B.; Masojídková, M.; Otmar, M.; Fiedler, P.; Ubik, K. Synthesis of N4-alkyl-5-azacytidines and their base-pairing with carbamoylguanidines. A contribution to explanation of the mutagenicity of 2′-deoxy-5-azacytidine Collect. Czech. Chem. Commun. 2003, 68, 711-743
63. Watson, J. D.; Crick, F. H. C. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid Nature 1953, 171, 737-738
64. Watson, J. D.; Crick, F. H. C. Genetical implications of the structure of deoxyribonucleic acid Nature 1953, 171, 964-967
65. von Borstel, R. C. Origins of spontaneous base substitutions Mutat. Res. 1994, 307, 131-140
66. Suen, W.; Spiro, T. G.; Sowers, L. C.; Fresco, J. R. Identification by UV resonance Raman spectroscopy of an imino tautomer of 5-hydroxy-2′- deoxycytidine, a powerful base analog transition mutagen with a much higher unfavored tautomer frequency than that of the natural residue 2′-deoxycytidine Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4500-4505
67. Kupfer, P. A.; Leumann, C. J. Synthesis, base pairing properties and trans-lesion synthesis by reverse transcriptases of oligoribonucleotides containing the oxidatively damaged base 5-hydroxycytidine Nucleic Acids Res. 2011, 39, 9422-9432
68. Stolarski, R.; Kierdaszuk, B.; Hagberg, C. E.; Shugar, D. Mechanism of hydroxylamine mutagenesis: tautomeric shifts and proton exchange between the promutagen N6-methoxyadenosine and cytidine Biochemistry 1987, 26, 4332-4337
69. Spengler, S.; Singer, B. Effect of tautomeric shift on mutation: N4-methoxycytidine forms hydrogen bonds with adenosine in polymers Biochemistry 1981, 20, 7290-7294
70. Hollecker, L.; Shi, J.; Du, J.; Wang, P.; Hassan, A.; Rachakonda, S.; Patterson, S. E.; Khan, N.; Hobbs, A.; Clark, J. L.; Chun, B.-K.; Iyodogan, P.; Lostia, S.; McBrayer, T. R.; Tharnish, P. M.; Otto, M. J.; Stuyver, L. J.; Schinazi, R. F.; Pankiewicz, K. W. Synthesis of Analogues of N4-Hydroxycytidine with Potential Anti-HCV Activity. In Frontiers in Nucleosides and Nucleic Acids; Schinazi, R. F.; Liotta, D. C., Eds.; IHL Press: College Park, GA, 2004; pp 319-338.
71. Graci, J. D.; Too, K.; Smidansky, E. D.; Edathil, J. P.; Barr, E. W.; Harki, D. A.; Galarraga, J. E.; Bollinger, J. M., Jr.; Peterson, B. R.; Loakes, D.; Brown, D. M.; Cameron, C. E. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues Antimicrob. Agents Chemother. 2008, 52, 971-979
72. Pyrc, K.; Bosch, B. J.; Berkhout, B.; Jebbink, M. F.; Dijkman, R.; Rottier, P.; van der Hoek, L. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle Antimicrob. Agents Chemother. 2006, 50, 2000-2008
73. Hernandez-Santiago, B. I.; Beltran, T.; Stuyver, L.; Chu, C. K.; Schinazi, R. F. Metabolism of the anti-hepatitis C virus nucleoside beta- d -N4-hydroxycytidine in different liver cells Antimicrob. Agents Chemother. 2004, 48, 4636-4642
74. Lawley, P. D.; Brookes, P. Ionization of DNA bases or base analogues as a possible explanation of mutagenesis, with special reference to 5-bromodeoxyuridine J. Mol. Biol. 1962, 4, 216-219
75. Sowers, L. C.; Goodman, M. F.; Eritja, R.; Kaplan, B.; Fazakerley, G. V. Ionized and wobble base-pairing for bromouracil-guanine in equilibrium under physiological conditions: a nuclear magnetic resonance study on an oligonucleotide containing a bromouracil-guanine base-pair as a function of pH J. Mol. Biol. 1989, 205, 437-447
76. Yu, H.; Eritja, R.; Bloom, L. B.; Goodman, M. F. Ionization of bromouracil and fluorouracil stimulates base mispairing frequencies with guanine J. Biol. Chem. 1993, 268, 15935-15943
77. Sowers, L. C.; Boulard, Y.; Fazakerley, G. V. Multiple structures for the 2-aminopurine-cytosine mispair Biochemistry 2000, 39, 7613-7620
78. Wempen, I.; Duschinsky, R.; Kaplan, L.; Fox, J. J. Thiation of nucleosides. IV. The synthesis of 5-fluoro-2′-deoxycytidine and related compounds J. Am. Chem. Soc. 1961, 83, 4755-4766
79. Pariente, N.; Sierra, S.; Airaksinen, A. Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus Virus Res. 2005, 107, 183-193
80. Sierra, S.; Davila, M.; Lowenstein, P. R.; Domingo, E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity J. Virol. 2000, 74, 8316-8323
81. Privat, E. J.; Sowers, L. C. A proposed mechanism for the mutagenicity of 5-formyluracil Mutat. Res. 1996, 354, 151-156
82. Bebenek, K.; Roberts, J. D.; Kunkel, T. A. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication J. Biol. Chem. 1992, 267, 3589-3596
83. Martinez, M. A.; Vartanian, J.-P.; Wain-Hobson, S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 and biased dNTP concentrations Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11787-11791
84. Gao, W. Y.; Johns, D. G.; Tanaka, M.; Mitsuya, H. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine Mol. Pharmacol. 1999, 55, 535-540
85. Lori, F.; Malykh, A. G.; Foli, A.; Maserati, R.; De Antoni, A.; Minoli, L.; Padrini, D.; Degli Antoni, A.; Barchi, E.; Jessen, H.; Wainberg, M. A.; Gallo, R. C.; Lisziewicz, J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance AIDS Res. Hum. Retroviruses 1997, 13, 1403-1409
86. Clouser, C. L.; Chauhan, J.; Bess, M. A.; van Oploo, J. L.; Zhou, D.; Dimick-Gray, S.; Mansky, L. M.; Patterson, S. E. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine Bioorg. Med. Chem. Lett. 2012, 22, 6642-6646
87. Harris, R. S.; Albin, J. S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics Expert Rev. Mol. Med. 2006, 12, e4
88. Malim, M. H.; Emerman, M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment Cell Host Microbe 2008, 3, 388-398
89. Hultquist, J. F.; Lengyel, J. A.; Refsland, E. W.; LaRue, R. S.; Lackey, L.; Brown, W. L.; Harris, R. S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1 J. Virol. 2011, 85, 11220-11234
90. Bishop, K. N.; Verma, M.; Kim, E. Y.; Wolinsky, S. M.; Malim, M. H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts PLoS Pathog. 2008, 4, e1000231
91. Schumacher, A. J.; Hache, G.; Macduff, D. A.; Brown, W. L.; Harris, R. S. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction J. Virol. 2008, 82, 2652-2660
92. Miyagi, E.; Opi, S.; Takeuchi, H.; Khan, M.; Goila-Gaur, R.; Kao, S.; Strebel, K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1 J. Virol. 2007, 81, 13346-13353
93. Browne, E. P.; Allers, C.; Landau, N. R. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent Virology 2009, 387, 313-321
94. Koito, A.; Ikeda, T. Apolipoprotein B mRNA-editing, catalytic polypeptide cytidine deaminases and retroviral restriction Wiley Interdiscip. Rev. RNA 2012, 3, 529-541
95. Mezei, M.; Minarovits, J. Reversal of HIV drug resistance and novel strategies to curb HIV infection: the viral infectivity factor vif as a target and tool of therapy Curr. Drug Targets 2006, 7, 881-885
96. Nathans, R.; Cao, H.; Sharova, N.; Ali, A.; Sharkey, M.; Stranska, R.; Stevenson, M.; Rana, T. M. Small-molecule inhibition of HIV-1 Vif Nat. Biotechnol. 2008, 26, 1187-1192
97. Smith, J. L.; Bu, W.; Burdick, R. C.; Pathak, V. K. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development Trends Pharmacol. Sci. 2009, 30, 638-646
98. Xiao, Z.; Ehrlich, E.; Luo, K.; Xiong, Y.; Yu, X. F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G FASEB J. 2007, 21, 217-222
99. Albin, J. S.; Harris, R. S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics Expert Rev. Mol. Med. 2010, 12, e4
100. Ali, A.; Wang, J.; Nathans, R. S.; Cao, H.; Sharova, N.; Stevenson, M.; Rana, T. M. Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication ChemMedChem 2012, 7, 1217-1229
101. Cen, S.; Peng, Z. G.; Li, X. Y.; Li, Z. R.; Ma, J.; Wang, Y. M.; Fan, B.; You, X. F.; Wang, Y. P.; Liu, F.; Shao, R. G.; Zhao, L. X.; Yu, L.; Jiang, J. D. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G J. Biol. Chem. 2010, 285, 16546-16552
102. Ejima, T.; Hirota, M.; Mizukami, T.; Otsuka, M.; Fujita, M. An anti-HIV-1 compound that increases steady-state expression of apolipoprotein B mRNA editing enzyme-catalytic peptide-like 3G Int. J. Mol. Med. 2011, 28, 612-616
103. Zuo, T.; Liu, D.; Lv, W.; Wang, X.; Wang, J.; Lv, M.; Huang, W.; Wu, J.; Zhang, H.; Jin, H.; Zhang, L.; Kong, W.; Yu, X. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and Elongin C J. Virol. 2012, 86, 5497-5507
104. Li, M.; Shandilya, S. M.; Carpenter, M. A.; Rathore, A.; Brown, W. L.; Perkins, A. L.; Harki, D. A.; Solberg, J.; Hook, D. J.; Pandey, K. K.; Parniak, M. A.; Johnson, J. R.; Krogan, N. J.; Somasundaran, M.; Ali, A.; Schiffer, C. A.; Harris, R. S. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G ACS Chem. Biol. 2012, 7, 506-517
105. Olson, M. E.; Li, M.; Harris, R. S.; Harki, D. A. Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold ChemMedChem 2013, 8, 112-117
106. Dapp, M. J.; Holtz, C. M.; Mansky, L. M. Concomitant lethal mutagenesis of human immunodeficiency virus type 1 J. Mol. Biol. 2012, 419, 158-170
107. Kamada, H.; Itoh, H.; Shibata, H.; Koshio, T.; Hayashi, A.; Nakagami, K. Inhibitory mechanism of mizoribine on the antibody production of mouse B cells stimulated with lipopolysaccharide Jpn. J. Pharmacol. 1997, 74, 323-330
108. Halle, S. 5-Azacytidine as a mutagen for arboviruses J. Virol. 1968, 2, 1228-1229
109. Mullins, J. I.; Heath, L.; Hughes, J. P.; Kicha, J.; Styrchak, S.; Wong, K. G.; Rao, U.; Hansen, A.; Harris, K. S.; Laurent, J. P.; Li, D.; Simpson, J. H.; Essigmann, J. M.; Loeb, L. A.; Parkins, J. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461 PLoS One 2011, 6, e15135
110. Harris, K. S.; Brabant, W.; Styrchak, S.; Gall, A.; Daifuku, R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis Antiviral Res. 2005, 67, 1-9
111. Landolph, J. R.; Jones, P. A. Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T 1/2 clone 8 and V79 cells Cancer Res. 1982, 42, 817-823
112. Janion, C.; Kajtaniak, E. Mutagenesis induced in amber P22 phages by base analogues Mutat. Res. 1979, 62, 191-195
113. Janion, C.; Glickman, B. W. N4-Hydroxycytidine: a mutagen specific for AT to GC transitions Mutat. Res. 1980, 72, 43-47
114. Sledziewska, E.; Janion, C. Mutagenic specificity of N4-hydroxycytidine Mutat. Res. 1980, 70, 11-16
115. Suzuki, T.; Moriyama, K.; Otsuka, C.; Loakes, D.; Negishi, K. Template properties of mutagenic cytosine analogues in reverse transcription Nucleic Acids Res. 2006, 34, 6438-6449
116. Munzel, M.; Lischke, U.; Stathis, D.; Pfaffeneder, T.; Gnerlich, F. A.; Deiml, C. A.; Koch, S. C.; Karaghiosoff, K.; Carell, T. Improved synthesis and mutagenicity of oligonucleotides containing 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine Chemistry (Easton) 2011, 17, 13782-13788
117. Nomura, A.; Negishi, K.; Hayatsu, H.; Kuroda, Y. Mutagenicity of N4-aminocytidine and its derivatives in Chinese hamster lung V79 cells. Incorporation of N4-aminocytosine into cellular DNA Mutat. Res. 1987, 177, 283-287
118. Sanchez-Jimenez, C.; Olivares, I.; de Avila Lucas, A. I.; Toledano, V.; Gutierrez-Rivas, M.; Lorenzo-Redondo, R.; Grande-Perez, A.; Domingo, E.; Lopez-Galindez, C. Mutagen-mediated enhancement of HIV-1 replication in persistently infected cells Virology 2012, 424, 147-153
119. Tapia, N.; Fernandez, G.; Parera, M.; Gomez-Mariano, G.; Clotet, B.; Quinones-Mateu, M.; Domingo, E.; Martinez, M. A. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection Virology 2005, 338, 1-8
120. Fujikawa, K.; Kamiya, H.; Kasai, H. The mutations induced by oxidatively damaged nucleotides, 5-formyl-dUTP and 5-hydroxy-dCTP,in Escherichia coli Nucleic Acids Res. 1998, 26, 4582-4587
121. Purmal, A. A.; Kow, Y. W.; Wallace, S. S. 5-Hydroxypyrimidine deoxynucleoside triphosphates are more efficiently incorporated into DNA by exonuclease-free Klenow fragment than 8-oxopurine deoxynucleoside triphosphates Nucleic Acids Res. 1994, 22, 3930-3935
122. Holland, J. J.; Domingo, E.; de la Torre, J. C.; Steinhauer, D. A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis J. Virol. 1990, 64, 3960-3962
123. Kaufman, E. R. Altered CTP synthetase activity confers resistance to 5-bromodeoxyuridine toxicity and mutagenesis Mutat. Res. 1986, 161, 19-27
124. Penman, B. W.; Wong, M.; Thilly, W. G. Mutagenicity of 5-halodeoxyuridines to diploid human lymphoblasts Life Sci. 1976, 19, 563-568
125. Bikbulatov, R. M.; Smol'nikova, N. M.; Strekalova, S. P.; Artsimovich, N. T.; Galushina, T. S. Study of the teratogenic, embryotoxic, mutagenic and immunodepressive action of 5-bromouridine Vopr. Virusol. 1982, 27, 101-103
126. Suzutani, T.; Machida, H. Analysis of toxic and mutagenic activities of antiherpesvirus nucleosides against HeLa cells and herpes simplex virus type 1 Mutat. Res. 1992, 267, 125-131
127. Anensen, H.; Provan, F.; Lian, A. T.; Reinertsen, S. H.; Ueno, Y.; Matsuda, A.; Seeberg, E.; Bjelland, S. Mutations induced by 5-formyl-2′- deoxyuridine in Escherichia coli include base substitutions that can arise from mispairs of 5-formyluracil with guanine, cytosine and thymine Mutat. Res. 2001, 476, 99-107
128. Klungland, A.; Paulsen, R.; Rolseth, V.; Yamada, Y.; Ueno, Y.; Wiik, P.; Matsuda, A.; Seeberg, E.; Bjelland, S. 5-Formyluracil and its nucleoside derivatives confer toxicity and mutagenicity to mammalian cells by interfering with normal RNA and DNA metabolism Toxicol. Lett. 2001, 119, 71-78
129. Bilimoria, M. H.; Gupta, S. V. Comparison of the mutagenic activity of 5-hydroxymethyldeoxyuridine with 5-substituted 2′-deoxyuridine analogs in the Ames Salmonella/microsome test Mutat. Res. 1986, 169, 123-127
130. Negishi, K.; Williams, D. M.; Inoue, Y.; Moriyama, K.; Brown, D. M.; Hayatsu, H. The mechanism of mutation induction by a hydrogen bond ambivalent, bicyclic N4-oxy-2′-deoxycytidine in Escherichia coli Nucleic Acids Res. 1997, 25, 1548-1552
131. Graci, J. D.; Harki, D. A.; Korneeva, V. S.; Edathil, J. P.; Too, K.; Franco, D.; Smidansky, E. D.; Paul, A. V.; Peterson, B. R.; Brown, D. M.; Loakes, D.; Cameron, C. E. Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue J. Virol. 2007, 81, 11256-11266
132. 4-ethenocytosine, and 4-amino-5-(imidazol-2-yl)imidazole Biochemistry 1993, 32, 12793-12801
133. Kim, M. Y.; Zhou, X.; Delaney, J. C.; Taghizadeh, K.; Dedon, P. C.; Essigmann, J. M.; Wogan, G. N. AlkB influences the chloroacetaldehyde-induced mutation spectra and toxicity in the pSP189 supF shuttle vector Chem. Res. Toxicol. 2007, 20, 1075-1083
134. Nair, D. T.; Johnson, R. E.; Prakash, L.; Prakash, S.; Aggarwal, A. K. Hoogsteen base pair formation promotes synthesis opposite the 1,N6-ethenodeoxyadenosine lesion by human DNA polymerase iota Nat. Struct. Mol. Biol. 2006, 13, 619-625
135. Levine, R. L.; Yang, I. Y.; Hossain, M.; Pandya, G. A.; Grollman, A. P.; Moriya, M. Mutagenesis induced by a single 1,N6-ethenodeoxyadenosine adduct in human cells Cancer Res. 2000, 60, 4098-4104
136. Negishi, K.; Oohara, K.; Urushidani, H.; Ohara, Y.; Hayatsu, H. Evaluation of the mutagenicity of 1,N6-ethenoadenine- and 3,N4-ethenocytosine- nucleosides in Salmonella typhimurium IARC Sci. Publ. 1986, 70, 293-297
137. Hill, F.; Williams, D. M.; Loakes, D.; Brown, D. M. Comparative mutagenicities of N6-methoxy-2,6-diaminopurine and N6-methoxyaminopurine 2′-deoxyribonucleosides and their 5′-triphosphates Nucleic Acids Res. 1998, 26, 1144-1149
138. Graci, J. D.; Too, K.; Smidansky, E. D.; Edathil, J. P.; Barr, E. W.; Harki, D. A.; Galarraga, J. E.; J. Martin Bollinger, J.; Peterson, B. R.; Loakes, D.; Brown, D. M.; Cameron, C. E. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues Antimicrob. Agents Chemother. 2008, 52, 971-979
139. Alderson, T. The mutagenic activity of 2-aminopurine and 2,6-diaminopurine on phage T4 grown on non-inhibited and chloramphenicol- inhibited cells of Escherichia coli B Mutat. Res. 1964, 106, 205-208
140. Le Page, F.; Sarasin, A.; Gentil, A.; Guy, A.; Cadet, J. Repair and mutagenic potency of 8-oxoG:A and 8-oxoG:C base pairs in mammalian cells Nucleic Acids Res. 1998, 26, 1276-1281